Survival of Naegleria fowleri primary amebic meningocephalitis (PAM) could be improved with an intensive multi-route chemo- and biotherapeutic regimen
Select Content Type
Clinical Guidelines
Authored By
Alisky, Joseph Martin
Authored On
Interests
Gastroenterology
Oncology
Radiology
Speciality
Gastroenterology
Radiology
Oncology
Book Detail
volume
71
ISSN
03069877
Publication Date
Actions
Download in App
Event Data
{"article_title":"Radiotherapy of anal canal cancer.","author":"Peiffert D, Huguet F, Vendrely V, Moureau-Zabotto L, Rivin Del Campo E, Cr\u00e9hange G, Dietmann AS, Moignier A","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"279","page_count":"","accession_number":"34955416","doi":"10.1016\/j.canrad.2021.11.015","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Anus Neoplasms radiotherapy; Carcinoma, Squamous Cell radiotherapy; Antineoplastic Combined Chemotherapy Protocols therapeutic use; Anus Neoplasms diagnostic imaging; Anus Neoplasms pathology; Anus Neoplasms therapy; Brachytherapy methods; Carcinoma, Squamous Cell diagnostic imaging; Carcinoma, Squamous Cell pathology; Carcinoma, Squamous Cell therapy; France; Humans; Neoplasm Staging; Organs at Risk diagnostic imaging; Patient Positioning; Postoperative Care; Radiation Oncology; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed; Tumor Burden","interest_area":["Gastroenterology"," Oncology"," Radiology"],"abstract":"We present the update of the recommendations of the French society for radiation oncology on external radiotherapy and brachytherapy of anal canal carcinoma. The following guidelines are presented: indications, treatment procedure, as well as dose and dose-constraints objectives, immediate postoperative management, post-treatment evaluation, and long-term follow-up. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34955416","isPdfLink":false,"isSAML":true,"an":"34955416","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211227 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 279-285. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"We present the update of the recommendations of the French society for radiation oncology on external radiotherapy and brachytherapy of anal canal carcinoma. The following guidelines are presented: indications, treatment procedure, as well as dose and dose-constraints objectives, immediate postoperative management, post-treatment evaluation, and long-term follow-up.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/dx.doi.org\/doi:10.1016\/j.mehy.2008.06.037","no_of_pages":"","authored_by":"Peiffert D, Huguet F, Vendrely V, Moureau-Zabotto L, Rivin Del Campo E, Cr\u00e9hange G, Dietmann AS, Moignier A","additionalInfo":{"Authored_By":"Alisky, Joseph Martin","Published_Date":"2008-12-01","Source":"Medical Hypotheses. Dec2008, Vol. 71 Issue 6, p969-971. 3p.","Languages":"English","Subjects":"Meningoencephalitis, Naegleria, Death (Biology), Rifampin, Public health, Chloramphenicol, Therapeutics","Title_Abbreviations":"Medical Hypotheses","Volume":"71"},"header":{"DbId":"edo","DbLabel":"Supplemental Index","An":"34955416","RelevancyScore":"806","PubType":"Academic Journal","PubTypeId":"academicJournal","PreciseRelevancyScore":"805.715148925781"},"plink":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&db=edo&AN=34955416&authtype=shib&custid=ns346513&group=main&profile=eds"}
["Alisky, Joseph Martin","2008-12-01","Medical Hypotheses. Dec2008, Vol. 71 Issue 6, p969-971. 3p.","English","Meningoencephalitis, Naegleria, Death (Biology), Rifampin, Public health, Chloramphenicol, Therapeutics","Medical Hypotheses","71"]
Description
Summary: Background: Naegleria fowleri primary amebic meningoencephalitis (PAM) has a very high mortality rate, probably exceeding 95%. A few people have survived after getting intravenous and intrathecal amphotericin, variably coupled with other agents that include dexamethasone, diflucan, chloramphenicol and rifampin, but even with prompt initiation of therapy, it is still a very uphill battle. Presentation of the hypothesis: Survival could be improved by combined intrathecal, intranasal and intravenous amphotericin, diflucan and rifampin, with aduvant intravenous chloramphenicol, muramyl dipeptide, azithromycin, minocycline and linezolid, intramuscular trifluoperazine, intranasal Cry1C protoxin and intrathecal anti-Naegleria immune globulin and dexamethasone. Hypothesis rationale: Instilling medications intranasally, intravenously and intrathecally would target the primary reservoir of infection and its common sites of spread. Intrathecal dexamethasone should attenuate cerebral edema, a primary cause of death in PAM. Azithromycin and minocycline appear to have synergy with amphotericin in killing N. fowleri in animal models, and the other agents, which also showed efficacy in animal models, should also be additive or synergistic as well. In essence one would approach PAM in the manner of chemotherapy for tuberculosis and cancer, with multidrug therapy to assure complete eradication. Testing the hypothesis: The hypothesis could be validated using murine and bovine models of N. fowleri PAM. Implications of the hypothesis: PAM may be emerging as a significant public health threat, underscoring the need for effective therapeutic regimens. [Copyright &y& Elsevier]
